Article
An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy.
International journal of pharmaceutics - 30 Aug 2020
Song Yubo, Xu Mingkai, Li Yongqiang, Li Yansheng, Gu Wu, Halimu Gulinare, Fu Xuanhe, Zhang Huiwen, Zhang Chenggang
Abstract excerpt
Solid tumors are intrinsically resistant to immunotherapy because of the major challenges including the immunosuppression and poor penetration of drugs and lymphocytes into solid tumors due to the complicated tumor microenvironment (TME). Our previous study has created a novel superantigen mutant ST-4 to efficiently active the T lymphocytes and alleviate immune suppression. In the present study, to accumulate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.